source
- FDA mandates label update for all GLP-1 drugs to warn of rare eye disease riskThe FDA issued a class‑wide labeling requirement for all approved GLP‑1 receptor agonists, adding a warning about non‑arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that…
- Forge Biologics VP sees AI and Ohio talent driving next wave of gene therapy manufacturingSamantha Piteri-Molina, vice president of business and strategy at Forge Biologics, said her focus is on getting gene therapies into patients' hands. She helped steer Forge through a $620 million…